Abstract
To evaluate the efficacy and safety of albumin-bound paclitaxel-based chemotherapy in treatment for patients with advanced esophageal cancer who failed in first-line chemotherapy. We collected29 advanced esophageal cancer patients who received albumin-bound paclitaxel-based chemotherapy fromJune 2009 to September 2013, and the efficacy and safety of the compound were evaluated. These patients were treated with 100-150mg/m2 nab-paclitaxel on days 1,8.The cycle was repeated every 3 weeks. Clinical efficacy was evaluated every two cycles. Of the 29 patients, two persons interrupted treatment because of adverse reactions, failed to evaluate efficacy effect. The rest of27 patients who could be evaluated for short-term response, 10 patients (37%) achieved partial response, 2 (7.4%) remained stable disease, and 15 (55.6%) had progressivedisease. The objective response rate was 37%, and the disease control rate was 44.4%.The median time to progression was 6.6 months.The major adverse reactions includedalopecia (62.07%), neutropenia (65.5%), gastrointestinalreaction (10.3%) andsensory neuropathy(6.8%). The albumin-bound paclitaxel- based chemotherapy is efficacy and safety in treatment for patients with advanced esophageal cancer who failed in first-line chemotherapy.
Highlights
Esophageal cancer is one of the most common cancers, which ishigh incidence in China.Esophageal squamous cell carcinoma (ESCC) may be associated with a worse prognosis after surgery than esophageal adenocarcinoma
To evaluate the efficacy and safety of albumin-bound paclitaxel-based chemotherapy in treatment for patients with advanced esophageal cancer who failed in first-line chemotherapy
The albumin-bound paclitaxelbased chemotherapy is efficacy and safety in treatment for patients with advanced esophageal cancer who failed in first-line chemotherapy
Summary
Esophageal cancer is one of the most common cancers, which ishigh incidence in China.Esophageal squamous cell carcinoma (ESCC) may be associated with a worse prognosis after surgery than esophageal adenocarcinoma. Due to few symptoms at the initial phase and the aggressive nature of esophageal cancer, advanced/ metastatic cases with unresectable tumors and recurrent cases after resection are frequently observed For those patients with unresectable esophageal tumor or metastatic disease, they should receive chemotherapy to and improve the quality of life and prolong the survival (Koshy et al, 2004; Karaosmanoglu et al, 2012). To evaluate the efficacy and safety of albumin-bound paclitaxel-based chemotherapy in treatment for patients with advanced esophageal cancer who failed in first-line chemotherapy. Materials and Methods: We collected advanced esophageal cancer patients who received albumin-bound paclitaxel-based chemotherapy fromJune 2009 to September 2013, and the efficacy and safety of the compound were evaluated. These patients were treated with 100-150mg/m2 nab-paclitaxel on days 1,8.The cycle was repeated every 3 weeks. Conclusions: The albumin-bound paclitaxelbased chemotherapy is efficacy and safety in treatment for patients with advanced esophageal cancer who failed in first-line chemotherapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
